Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2012.48.4147 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Promising Effect of Tocilizumab on Chronic Antibody-Mediated Rejection (cAMR) of Kidney Transplant.
Pharmaceutics
January 2025
Department of General and Transplant Surgery, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
: Chronic antibody-mediated rejection (cAMR) constitutes a serious challenge in the long-term success of organ transplantation. It is associated with donor-specific antibodies (DSAs) which activate a complement pathway in response to the presence of human leukocyte antigens (HLAs) on the graft, which results in chronic inflammation and leads to graft dysfunction. One of the recent promising methods of cAMR treatment is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody referred to as Tocilizumab (TCZ).
View Article and Find Full Text PDFAssessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives.
Biomedicines
January 2025
Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo 181-0004, Japan.
Behçet's disease is an autoinflammatory disorder characterized by relapsing and remitting vasculitis that can manifest in various forms, including gastrointestinal Behçet's disease (GIBD). Its complications (e.g.
View Article and Find Full Text PDFRETRACTED: Di Paola et al. Environmental Risk Assessment of Dexamethasone Sodium Phosphate and Tocilizumab Mixture in Zebrafish Early Life Stage (). 2022, , 279.
Toxics
January 2025
Department of Chemical, Biological, Pharmaceutical, and Environmental Science, University of Messina, 98166 Messina, Italy.
The journal retracts the article "Environmental risk assessment of mixture of COVID-19 treating pharmaceutical drugs in zebrafish early life stage ()" [...
View Article and Find Full Text PDFObjective: Scleroderma-associated autoantibodies (SSc-Abs) are specific in participants (pts) with systemic sclerosis and are associated with organ involvement. Our objective was to assess the influence of baseline SSc-Abs on the trajectories of the clinical outcome assessments (COAs) in a phase III randomized controlled trial.
Methods: We used data on both the groups who received placebo (Pbo) and tocilizumab from the focuSSced trial.
Tocilizumab - a disease-modulating treatment for thyroid associated ophthalmopathy?
Orbit
January 2025
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Purpose: To analyze Tocilizumab (TCZ, an interleukin 6 inhibitor) as a second-line treatment for thyroid-associated ophthalmopathy (TAO).
Methods: In this retrospective observational study, the charts of patients with moderately severe to severe TAO who received intravenous Tocilizumab as a second-line treatment 2020-2023 were reviewed.
Results: Twenty-three patients were enrolled in the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!